OTCPK:NBGV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

NewBridge Global Ventures, Inc., through its subsidiaries, cultivates, manufactures, and distributes medical and recreational cannabis products in California.


Snowflake Analysis

Overvalued with worrying balance sheet.

Share Price & News

How has NewBridge Global Ventures's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NBGV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

17.2%

NBGV

0.2%

US Pharmaceuticals

0.5%

US Market


1 Year Return

-24.1%

NBGV

14.3%

US Pharmaceuticals

18.0%

US Market

Return vs Industry: NBGV underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.

Return vs Market: NBGV underperformed the US Market which returned 18.7% over the past year.


Shareholder returns

NBGVIndustryMarket
7 Day17.2%0.2%0.5%
30 Day-29.3%1.9%4.5%
90 Day-1.0%1.5%19.7%
1 Year-24.1%-24.1%17.3%14.3%20.5%18.0%
3 Yearn/a33.9%24.0%46.3%36.8%
5 Yearn/a39.9%24.1%87.2%66.8%

Price Volatility Vs. Market

How volatile is NewBridge Global Ventures's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is NewBridge Global Ventures undervalued compared to its fair value and its price relative to the market?

1.01x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NBGV's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NBGV's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NBGV is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: NBGV is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NBGV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NBGV is good value based on its PB Ratio (1x) compared to the US Pharmaceuticals industry average (3.2x).


Next Steps

Future Growth

How is NewBridge Global Ventures forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

33.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NewBridge Global Ventures has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has NewBridge Global Ventures performed over the past 5 years?

-3,973.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: NBGV is currently unprofitable.

Growing Profit Margin: NBGV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if NBGV's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare NBGV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NBGV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.1%).


Return on Equity

High ROE: NBGV has a negative Return on Equity (-78.17%), as it is currently unprofitable.


Next Steps

Financial Health

How is NewBridge Global Ventures's financial position?


Financial Position Analysis

Short Term Liabilities: NBGV's short term assets ($491.4K) do not cover its short term liabilities ($8.5M).

Long Term Liabilities: NBGV's short term assets ($491.4K) do not cover its long term liabilities ($1.5M).


Debt to Equity History and Analysis

Debt Level: NBGV's debt to equity ratio (35.5%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if NBGV's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if NBGV has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if NBGV has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is NewBridge Global Ventures's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NBGV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NBGV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NBGV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NBGV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NBGV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Chris Bourdon

0.83

Tenure

Mr. Chris Bourdon serves as Chairman and Chief Executive officer of NewBridge Global Ventures, Inc. since October 16, 2019. Mr. Bourdon is Founder, Managing Director and Managing Partner of The Last90. He ...


Leadership Team

NamePositionTenureCompensationOwnership
Chris Bourdon
Chairman & CEO0.83yrno datano data
Douglas Mancosky
Interim Chief Technology Officer0.83yrno datano data
Patrick Tang
Chief Compliance Officer1.67yrsno data0.45%
$ 65.7k
Jesse Magallanes
Senior Vice President of Corporate Developmentno datano datano data
Eric Anderson
Chief Strategy Officer1yrno datano data
Sandra Ribble
Corporate Controller1.58yrsno datano data
J. Tate
Secretary2.5yrsno data0.044%
$ 6.4k

1.3yrs

Average Tenure

53yo

Average Age

Experienced Management: NBGV's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Chris Bourdon
Chairman & CEO0.83yrno datano data
Arthur Kwan
Director0.83yrno datano data
Eric Tran
Director1.17yrsno data13.46%
$ 2.0m
Robert Szwajkos
Director0.50yrno datano data

0.8yrs

Average Tenure

Experienced Board: NBGV's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.8%.


Top Shareholders

Company Information

NewBridge Global Ventures, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NewBridge Global Ventures, Inc.
  • Ticker: NBGV
  • Exchange: OTCPK
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$14.597m
  • Shares outstanding: 73.72m
  • Website: https://www.newbridgegv.com

Number of Employees


Location

  • NewBridge Global Ventures, Inc.
  • 2545 Santa Clara Avenue
  • Alameda
  • California
  • 94501
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NBGVOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJul 2018

Biography

NewBridge Global Ventures, Inc., through its subsidiaries, cultivates, manufactures, and distributes medical and recreational cannabis products in California. It also offers consulting services to cultivat ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/14 12:32
End of Day Share Price2020/08/12 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.